Related MeSH Hierarchy (11)
Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Genital Diseases, Female » Adnexal Diseases » Ovarian Diseases » Ovarian Neoplasms » Hereditary Breast and Ovarian Cancer Syndrome
Diseases [C] » Neoplasms [C04] » Neoplastic Syndromes, Hereditary » Hereditary Breast and Ovarian Cancer Syndrome
Diseases [C] » Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] » Genetic Diseases, Inborn » Neoplastic Syndromes, Hereditary » Hereditary Breast and Ovarian Cancer Syndrome
Diseases [C] » Skin and Connective Tissue Diseases [C17] » Skin Diseases » Breast Diseases » Breast Neoplasms » Hereditary Breast and Ovarian Cancer Syndrome
Diseases [C] » Endocrine System Diseases [C19] » Endocrine Gland Neoplasms » Ovarian Neoplasms » Hereditary Breast and Ovarian Cancer Syndrome
Diseases [C] » Endocrine System Diseases [C19] » Gonadal Disorders » Ovarian Diseases » Ovarian Neoplasms » Hereditary Breast and Ovarian Cancer Syndrome
Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Breast Neoplasms » Hereditary Breast and Ovarian Cancer Syndrome
Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Endocrine Gland Neoplasms » Ovarian Neoplasms » Hereditary Breast and Ovarian Cancer Syndrome
Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Urogenital Neoplasms » Genital Neoplasms, Female » Ovarian Neoplasms » Hereditary Breast and Ovarian Cancer Syndrome
Diseases [C] » Urogenital Diseases [C12] » Genital Diseases » Genital Diseases, Female » Adnexal Diseases » Ovarian Diseases » Ovarian Neoplasms » Hereditary Breast and Ovarian Cancer Syndrome
Diseases [C] » Urogenital Diseases [C12] » Urogenital Neoplasms » Genital Neoplasms, Female » Ovarian Neoplasms » Hereditary Breast and Ovarian Cancer Syndrome
Description
Autosomal dominant HEREDITARY CANCER SYNDROME in which a mutation most often in either BRCA1 or BRCA2 is associated with a significantly increased risk for breast and ovarian cancers. MeSH
Hierarchy View
Phase 2 Indicated Drugs (1)
Phase 1 Indicated Drugs (3)
Other Experimental Indicated Drugs (6)
Organization Involved with Phase 2 Indications (5)
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (1)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
